Swiss implant manufacturer Nobel Biocare has signed an exclusive agreement with Wyeth Pharmaceutical manufacturer of Bone Morphogenic Protein rhBMP-2. They claim that: `TiUnite(r) will serve as the foundation for the next generation of dental implants with the potential of eliminating the need to graft and use of membranes. Nobel Biocare is currently in clinical testing of an implant designed to create its own bone. This implant will be treated with a bone morphogenetic protein rhBMP-2 (a recombinant version of a naturally occurring human protein).` and furthermore they claim: `it will drastically change the indications for dental implants. Patients that currently do not qualify for implants will now be able to be treated.`.